Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Kanki, Phyllis
PropertyValue
overview My research centers on the virology, molecular epidemiology of HIV in Africa along with implementation science work to improve HIV outcomes. I have worked in West Africa since the 1980s and in 2000, I created and directed the AIDS Prevention Initiative in Nigeria (APIN), with a $25 million grant from the Bill & Melinda Gates Foundation. Since 2004, I led the Harvard President’s Emergency Plan for AIDS Relief (PEPFAR) providing prevention, care and HIV antiretroviral therapy in Nigeria, Botswana, and Tanzania. In addition to the capacity building for clinical, laboratory and research capabilities, the program provided treatment for over 160,000 AIDS patients. The PEPFAR program in Nigeria has developed an extensive electronic medical record system that provides real time access to >100,000 patients on antiretroviral treatment. These databases allow us to promote better clinical care and also to answer operational research questions dealing with the efficacy of ART and PMTCT interventions and modulators of this response. Along with Nigerian colleagues, my research group has addressed topics including with HIV co-infections, determinants of ART efficacy and evaluation of PMTCT interventions. In an effort to optimize HIV outcomes we have characterized losses to follow-up in HIV care, treatment and PMTCT interventions and HIV drug resistance. I am currently co-PI for a trial of point of care HIV viral load monitoring to enhance ART outcomes and retention on ART in Nigeria. My long-term research collaborations in West Africa have also incorporated training and research capacity building. I served as the co-principal investigator of the Harvard School of Public Health AITRIP (1988-2013) and I currently lead the Harvard component for NIH Medical Education Partnership Initiatives (MEPI) at the University of Ibadan, Jos and Lagos. These programs seek to enhance research capacity for junior faculty. I have provided mentoring for more than 60 doctoral students or fellows from the US and African countries and I am an honorary faculty member at the University of Ibadan and University of Jos in Nigeria. Following the previous epidemics of Ebola and Zika virus, we have documented the presence of ZIKV infection in Senegalese and Nigerian fever patients over ~ 25 years, demonstrating the endemicity of this unique arbovirus in the region. We have described the longevity, specificity and cross reactivity of T cell responses to ZIKV and DENV NS3. We have also characterized the T cell responses in survivors and exposed health care workers from the 2015 Nigeria EBOV outbreak. We are currently conducting an NIH funded study on the impact of Zika virus infection on pregnancy outcomes in Nigeria. In response to the current SARS-CoV-2 pandemic, I am working with e25Bio an MIT engine laboratory towards development of point of care antigen and antibody assays as well as a pan-subgroup 2b betacoronavirus assays that may serve as zoonotic surveillance tool for future emergent SARS-like viruses.
One or more keywords matched the following items that are connected to Kanki, Phyllis
Item TypeName
Academic Article Highly active antiretroviral therapy and viral response in HIV type 2 infection.
Academic Article Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
Academic Article Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay.
Academic Article Humoral aspects of anti-HIV immune responses in Zairians with AIDS: lower antigenemia does not correlate with immune complex levels.
Academic Article Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response.
Academic Article Response: HIV-2 and Natural Protection Against HIV-1 Infection.
Academic Article Scaling up HIV treatment and prevention through national responses and innovative leadership.
Academic Article Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
Academic Article Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals.
Academic Article Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Academic Article Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
Academic Article Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.
Academic Article Haematological and biochemical response to treatment of HIV-1 infection with a combination of nevirapine + stavudine + lamivudine in Lagos Nigeria.
Grant Reaching 90% target of HIV viral suppression: The role of point of care VL monitoring in resources constrained settings
Academic Article Sustained Specific and Cross-Reactive T Cell Responses to Zika and Dengue Virus NS3 in West Africa.
Academic Article A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals.
Academic Article T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses.
Academic Article Erratum for Herrera et al., "T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses".
Grant Zika Virus in Pregnancy in Nigeria
Grant Improving Comprehensive AIDS Response Enhanced for Sustainability (iCARES)
Search Criteria
  • Epidemic
  • Response
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.